Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT06740240
Overview
As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.
Sponsor
First Affiliated Hospital of Fujian Medical University
Phase
Early Phase 1
Contacts
Weibing Miao, MD
miaoweibing@126.com
+86-0591-87981618
Rong Lin, MD
linrong1214@foxmail.com
+86-0591-87981619
ClinicalTrials.gov
NCT06740240Drug / Compound
Help us improve your experience